Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.

< BACK TO ARCHIVE


2020 Sep 08


J Allergy Clin Immunol Pract


http://www.ncbi.nlm.nih.gov/pubmed/32916325?dopt=Abstract

Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.

Authors

Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.
Phinyo P, Koompawichit P, Nochaiwong S, Tovanabutra N, Chiewchanvit S, Chuamanochan M
J Allergy Clin Immunol Pract. 2020 Sep 08.
PMID: 32916325.

Abstract

Licensed dose second-generation H1-antihistamines (sgAHs) are the first-line treatment in chronic spontaneous urticaria (CSU). However, the available evidence up to the present is insufficient to rank sgAHs in terms of their efficacy.
Read This Paper